Logo image of DBVT

DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Fundamental Analysis

USA - NASDAQ:DBVT - US23306J2006 - ADR

16.31 USD
-0.64 (-3.78%)
Last: 10/20/2025, 4:30:01 PM
Fundamental Rating

2

DBVT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of DBVT have multiple concerns. DBVT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DBVT had negative earnings in the past year.
DBVT had a negative operating cash flow in the past year.
In the past 5 years DBVT always reported negative net income.
DBVT had a negative operating cash flow in each of the past 5 years.
DBVT Yearly Net Income VS EBIT VS OCF VS FCFDBVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -85.56%, DBVT is not doing good in the industry: 71.72% of the companies in the same industry are doing better.
DBVT's Return On Equity of -142.22% is on the low side compared to the rest of the industry. DBVT is outperformed by 62.17% of its industry peers.
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBVT Yearly ROA, ROE, ROICDBVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Gross Margin of DBVT (91.34%) is better than 92.13% of its industry peers.
DBVT's Gross Margin has declined in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBVT Yearly Profit, Operating, Gross MarginsDBVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

3

2. Health

2.1 Basic Checks

DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBVT has more shares outstanding than it did 1 year ago.
DBVT has more shares outstanding than it did 5 years ago.
DBVT has a worse debt/assets ratio than last year.
DBVT Yearly Shares OutstandingDBVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
DBVT Yearly Total Debt VS Total AssetsDBVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 1.35, we must say that DBVT is in the distress zone and has some risk of bankruptcy.
DBVT has a Altman-Z score of 1.35. This is in the better half of the industry: DBVT outperforms 62.36% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that DBVT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, DBVT is doing worse than 62.36% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 1.35
ROIC/WACCN/A
WACC8.09%
DBVT Yearly LT Debt VS Equity VS FCFDBVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.45 indicates that DBVT has no problem at all paying its short term obligations.
DBVT has a Current ratio of 2.45. This is in the lower half of the industry: DBVT underperforms 69.66% of its industry peers.
A Quick Ratio of 2.45 indicates that DBVT has no problem at all paying its short term obligations.
DBVT has a Quick ratio of 2.45. This is in the lower half of the industry: DBVT underperforms 67.23% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
DBVT Yearly Current Assets VS Current LiabilitesDBVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for DBVT have decreased strongly by -22.83% in the last year.
The Revenue for DBVT has decreased by -72.49% in the past year. This is quite bad
Measured over the past years, DBVT shows a very negative growth in Revenue. The Revenue has been decreasing by -22.35% on average per year.
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%

3.2 Future

The Earnings Per Share is expected to grow by 23.50% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 146.91% on average over the next years. This is a very strong growth
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue Next Year2930.57%
Revenue Next 2Y1762.26%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DBVT Yearly Revenue VS EstimatesDBVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
DBVT Yearly EPS VS EstimatesDBVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DBVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBVT Price Earnings VS Forward Price EarningsDBVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBVT Per share dataDBVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as DBVT's earnings are expected to grow with 23.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.64%
EPS Next 3Y23.5%

More info and screens

0

5. Dividend

5.1 Amount

DBVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (10/20/2025, 4:30:01 PM)

16.31

-0.64 (-3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners53.95%
Inst Owner Change0.02%
Ins Owners0.06%
Ins Owner Change-0.29%
Market Cap446.45M
Analysts80
Price Target12.15 (-25.51%)
Short Float %0.08%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.58%
PT rev (3m)7.67%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)-21.09%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-13.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-29.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 117.49
P/FCF N/A
P/OCF N/A
P/B 5.18
P/tB 5.18
EV/EBITDA N/A
EPS(TTM)-4.89
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-3.22
FCFYN/A
OCF(TTM)-3.21
OCFYN/A
SpS0.14
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.34%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.61%
Cap/Sales 8.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z 1.35
F-Score2
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.82%
EPS Next Y1.69%
EPS Next 2Y37.64%
EPS Next 3Y23.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-72.49%
Revenue growth 3Y-10.07%
Revenue growth 5Y-22.35%
Sales Q2Q%26.18%
Revenue Next Year2930.57%
Revenue Next 2Y1762.26%
Revenue Next 3Y277.96%
Revenue Next 5Y146.91%
EBIT growth 1Y-31.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.07%
EBIT Next 3Y16.69%
EBIT Next 5YN/A
FCF growth 1Y0.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A